Wordt geladen...
Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
Immunoglobulin (Ig)-replacement therapy represents the mainstay of treatment for patients with primary antibody deficiency and is administered either intravenously (IVIg) or subcutaneously (SCIg). While hyaluronidase has been used in clinical practice for over 50 years, the development of a high-pur...
Bewaard in:
| Gepubliceerd in: | Immunotargets Ther |
|---|---|
| Hoofdauteur: | |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Dove Medical Press
2013
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4928364/ https://ncbi.nlm.nih.gov/pubmed/27471693 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/ITT.S31136 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|